+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine



Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine



Annals of Oncology 12(12): 1761-1763



The hand-foot syndrome (palmar-plantar erythrodysesthesia) is a side-effect which is associated with several cytotoxic agents (e.g. 5-fluorouracil, UFT, capecitabine, cytarabine, doxorubicin, liposomal-encapsulated doxorubicin). An association with a prolonged infusion of high doses of vinorelbine has also been described. To date a hand-foot syndrome after gemcitabine or short infusions of vinorelbine has not been reported before. The patient described here had a non-small-cell lung cancer stage IIIB disease and developed a hand-foot syndrome after short infusions of standard-dose chemotherapy of a combination with gemcitabine and vinorelbine.

(PDF emailed within 1 workday: $29.90)

Accession: 046211118

Download citation: RISBibTeXText

PMID: 11843256


Related references

Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Investigational New Drugs 28(5): 659-669, 2010

Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy. American Journal of Clinical Oncology 26(6): 567-570, 2003

Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. Journal of Clinical Pharmacology 44(10): 1166-1172, 2004

Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefinitib, vinorelbine, gemcitabine or doxorubicin. Proceedings of the American Association for Cancer Research Annual Meeting 44: 138, July, 2003

Combination chemotherapy of gemcitabine and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer 46(3): 377-378, 2004

Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan. Seminars in Oncology 28(3 Suppl 9): 15-20, 2001

Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. Cancer Research and Treatment 40(2): 81-86, 2008

High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy. Annals of Oncology 14(11): 1691-1692, 2003

Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: A phase II trial. European Journal of Cancer 38(5): 654-660, March, 2002

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 109(9): 1863-1869, 2007

An elderly patient with advanced non-small-cell lung cancer that responded remarkably to combination chemotherapy of vinorelbine and gemcitabine. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 29(3): 439-442, 2002

Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. Anticancer Research 28(5b): 3019-3025, 2008

A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma. Journal of the College of Physicians and Surgeons--Pakistan 23(6): 397-400, 2013

Cisplatin/gemcitabine vs cisplatin/gemcitabine/vinorelbine vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine in advanced non-small cell lung cancer Final results of a Spanish lung cancer group phase III trial. European Journal of Cancer 37(Supplement 6): S28, October, 2001